156P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1-refractory/resistant unresectable or metastatic melanoma from a phase Ib studyC. Cui, Jun Guo, Hongming Pan et al.|Annals of Oncology|2021Cited by 1